BridgeBio Oncology Therapeutics presented preliminary data for its three lead oncology programs, revealing a 65% confirmed overall response rate in 17 non‑small cell lung cancer patients with KRAS G12C for BBO‑8520. The cohort also showed a favorable liver toxicity profile, with no grade 3 or higher hepatotoxicity reported.
BBO‑11818, a pan‑KRAS ON/OFF inhibitor, achieved the first publicly disclosed monotherapy response in a pretreated pancreatic ductal adenocarcinoma patient, with a 56% reduction in tumor burden and a well‑tolerated safety profile.
BBO‑10203, a novel RAS:PI3Kα breaker, demonstrated no hyperglycemia of any grade in patients, even without restrictions on baseline glucose levels, and identified a 500 mg daily dose for upcoming expansion cohorts.
The data were presented in a webcast at 8:30 a.m. Eastern Time, and the company outlined planned expansion cohorts and combination studies with standard‑of‑care therapies, positioning the pipeline for potential regulatory milestones in 2026.
Management emphasized the differentiated safety profiles and the potential of BBO‑8520 as a front‑line combination partner with pembrolizumab. CEO Eli Wallace said, “Today’s data underscore the strength of our differentiated precision oncology portfolio targeting RAS and PI3Kα.” Chief Medical and Development Officer Yong (Ben) Ben added, “BBO‑8520 continues to demonstrate a favorable benefit‑risk profile, with encouraging efficacy data, a generally tolerable safety profile, and a potentially differentiated liver toxicity profile, both as monotherapy and in combination with pembrolizumab.”
Analysts responded positively, with Morgan Stanley assigning an Overweight rating and a $20 price target, reflecting confidence in the pipeline’s potential to address unmet needs in RAS‑driven cancers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.